Lu et al.35 found that CEP55 was highly expressed in pancreatic ductal adenocarcinoma cells and that its expression in pancreatic patients receiving immunotherapy could reflect the efficacy and prognosis of immunotherapy. This evidence concerns the gene CEP55 and pancreatic ductal adenocarcinoma.